ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
Inhibition of prostatic cancer growth by ginsenoside Rh2.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Comprehensive PRISMA Based Systematic Review: Exploring the Phytochemistry, Pharmacological Profile and Clinical aspects ofCurrent topics in medicinal chemistry · 2025Pooled it
- Green chemistry for prostate health: exploring nature's toolbox against cancer, inflammation, and hyperplasia.Molecular diversity · 2026Review
- Pulsatilla Saponin D Suppresses Proliferation and Induces Apoptosis in Human Prostatic Cells.Cells · 2025Article
- Pharmacokinetics and pharmacodynamics of Rh2 and aPPD ginsenosides in prostate cancer: a drug interaction perspective.Cancer chemotherapy and pharmacology · 2023Review
- Review
- Targeting transforming growth factor-β signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin.Clinical and translational medicine · 2022Review
- Glycosyltransformation of ginsenoside Rh2 into two novel ginsenosides using recombinant glycosyltransferase fromJournal of ginseng research · 2021Article
- Prostate cancer: Therapeutic prospect with herbal medicine.Current research in pharmacology and drug discovery · 2021Review
- How Does Ginsenoside Rh2 Mitigate Adipogenesis in Cultured Cells and Obese Mice?Molecules (Basel, Switzerland) · 2020Article
- Black Ginseng and Its Saponins: Preparation, Phytochemistry and Pharmacological Effects.Molecules (Basel, Switzerland) · 2019Review
- Ginsenoside Rh2 inhibits prostate cancer cell growth through suppression of microRNA-4295 that activates CDKN1A.Cell proliferation · 2018Article
- Induction of apoptosis in prostate cancer by ginsenoside Rh2.Oncotarget · 2018Article
- Ginsenoside Rh2 enhances the antitumor immunological response of a melanoma mice model.Oncology letters · 2017Article
- Saponins from Chinese Medicines as Anticancer Agents.Molecules (Basel, Switzerland) · 2016Review
- Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase.Journal of ginseng research · 2016Article
- Anticancer Activities of Protopanaxadiol- and Protopanaxatriol-Type Ginsenosides and Their Metabolites.Evidence-based complementary and alternative medicine : eCAM · 2016Review
- Adiponectin inhibits VEGF-A in prostate cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ginsenoside Rh2 (GRh2) has been reported to have therapeutic effects on some types of cancer, but its effect on prostatic cancer has not been extensively evaluated. Here, we show that GRh2 can substantially inhibit the growth of prostatic cancer in vivo and in vitro. Moreover, the inhibition of the tumor growth appeared to result from a combined inhibitory effect on tumor cell proliferation and tumor cell invasiveness. Further analyses suggest that GRh2 seemed to activate transforming growth factor β (TGFβ) receptor signaling in prostatic cancer cells, which subsequently inhibits cell proliferation and invasion through regulating cell-cycle controllers and (MMPs), respectively. Taken together, our data reveal an essential anti-prostatic cancer effect of GRh2 and demonstrate that this effect is through augment of TGFβ receptor signaling in the prostatic cancer cells. GRh2 thus appears to be a promising therapy for prostatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.